Cargando…

Current Smoking Is Associated with a Poor Visual Acuity Improvement after Intravitreal Ranibizumab Therapy in Patients with Exudative Age-Related Macular Degeneration

In this study, the risk factors that may influence visual improvement after intravitreal ranibizumab (IVR) treatment for exudative age-related macular degeneration (AMD) were examined. From 2008 to 2012, 420 patients (448 eyes) with exudative AMD were prospectively registered at Seoul National Unive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sangmoon, Song, Su Jeong, Yu, Hyeong Gon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653092/ https://www.ncbi.nlm.nih.gov/pubmed/23678271 http://dx.doi.org/10.3346/jkms.2013.28.5.769

Ejemplares similares

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
por: Canan, Handan, et al.
Publicado: (2014)

Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05
por: Koch, Raphael, et al.
Publicado: (2015)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
por: Narayan, Daniel Sanju, et al.
Publicado: (2015)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
por: Suzuki, Hiroyuki, et al.
Publicado: (2017)

FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity
por: Monés, Jordi, et al.
Publicado: (2012)

Intravitreal Ranibizumab for Subfoveal Choroidal Neovascularization from Age-Related Macular Degeneration with Combined Severe Diabetic Retinopathy
por: Han, So Young, et al.
Publicado: (2015)

Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration
por: Williams, Gwyn Samuel, et al.
Publicado: (2015)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
por: Nakamura, Tomoko, et al.
Publicado: (2012)

Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes
por: Figurska, Małgorzata, et al.
Publicado: (2011)

AFLIBERCEPT AFTER RANIBIZUMAB INTRAVITREAL INJECTIONS IN EXUDATIVE AGE–RELATED MACULAR DEGENERATION: The ARI2 Study
por: Blanco-Garavito, Rocio, et al.
Publicado: (2018)

Intravitreal Anti-vascular Endothelial Growth Factor for Typical Exudative Age-related Macular Degeneration in Eyes with Good Baseline Visual Acuity
por: Chang, Young Suk, et al.
Publicado: (2014)

Intravitreal aflibercept for exudative age-related macular degeneration with good visual acuity: 2-year results of a prospective study
por: Sakamoto, Shinichi, et al.
Publicado: (2018)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
por: Griffin, David R., et al.
Publicado: (2014)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
por: Perdicchi, Andrea, et al.
Publicado: (2015)

Foveal Exudative Macroaneurysm Treated with Intravitreal Ranibizumab
por: Menezes, Carlos, et al.
Publicado: (2015)

Visual acuity loss associated with excessive “dry macula” in exudative age-related macular degeneration
por: Takahashi, Hidenori, et al.
Publicado: (2018)

Ranibizumab plus fufang xueshuantong capsule versus ranibizumab alone for exudative age-related macular degeneration
por: Pan, Hai-Tao, et al.
Publicado: (2020)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
por: Hamid, Mohamed A., et al.
Publicado: (2021)

The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
por: Gungel, Hulya, et al.
Publicado: (2014)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
por: Sabour-Pickett, Sarah, et al.
Publicado: (2013)

Lucentis(®) using Visudyne(®) study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration
por: Chen, Eric, et al.
Publicado: (2010)

Switching from Intravitreal Ranibizumab to Bevacizumab for Age-Related Macular Degeneration
por: Yamada, Kisaburo, et al.
Publicado: (2011)

Functional outcomes after multiple treatments with ranibizumab in neovascular age-related macular degeneration beyond visual acuity
por: Feigl, Beatrix, et al.
Publicado: (2007)

The effect of ranibizumab versus photodynamic therapy on DNA damage in patients with exudative macular degeneration
por: Mozaffarieh, M, et al.
Publicado: (2009)

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration
por: Barthelmes, Daniel, et al.
Publicado: (2016)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
por: Koike, Naoko, et al.
Publicado: (2019)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
por: Basheer, Khadijah, et al.
Publicado: (2015)

Treatment of peripheral exudative hemorrhagic chorioretinopathy by intravitreal injections of ranibizumab
por: Takayama, Kei, et al.
Publicado: (2012)

Five-Year Outcome of Aflibercept Monotherapy for Exudative Age-Related Macular Degeneration with Good Baseline Visual Acuity
por: Kikushima, Wataru, et al.
Publicado: (2021)

Macular Hole Formation After Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
por: Mukherjee, Chandoshi, et al.
Publicado: (2015)

Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
por: Hariprasad, Seenu M., et al.
Publicado: (2012)

Neovascular Age‐Related Macular Degeneration: A Visual Acuity Model of Natural Disease Progression and Ranibizumab Treatment Effect
por: Mulyukov, Zufar, et al.
Publicado: (2018)

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
por: Schauwvlieghe, A. M. E., et al.
Publicado: (2016)

The Effect of Ranibizumab on Normal Neurosensory Retina in the Eyes of Patients with Exudative Age Related Macular Degeneration
por: Makri, Olga E., et al.
Publicado: (2017)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
por: Karagiannis, Dimitrios, et al.
Publicado: (2017)

Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration
por: Suzuki, Misa, et al.
Publicado: (2014)

Subretinal Neovascular Membrane in Wet Age-Related Macular Degeneration Managed With Intravitreal Ranibizumab
por: Sharma, Tanishq S, et al.
Publicado: (2021)

Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study
por: Oshima, Yuji, et al.
Publicado: (2021)

Foveal threshold and photoreceptor integrity for prediction of visual acuity after intravitreal aflibercept on age-related macular degeneration
por: Sakai, Tsutomu, et al.
Publicado: (2018)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population: letter to the editor
por: Stewart, Michael W
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_klmuo8gq0bic7il1h7l31qora6